During the latest earnings call, Moderna CEO Stéphane Bancel was pleased with the cost efficiency achieved during the quarter ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

The vaccine maker reported a surprise profit and higher revenue than expected. CEO Stéphane Bancel said the company is ahead ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

(NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. 'We are honored ...

Conversations focused on Innovative Whole Health Strategies: Where Care, Science, AI And Economics Converge Judy Faulkner, Stéphane Bancel and Annie Lamont to Speak at 2024 Summit ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Costochondritis — a benign condition that causes inflammation of the cartilage connecting your ribs to your breastbone. Also ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna President Stephen Hoge, M.D., has taken on an expanded role, adding new responsibilities overseeing Moderna’s commercial organization. As President, Dr. Hoge will now be responsible for ...